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Abstract
Our recent studies have shown that co-activation of
Gq and Gi proteins by 5-hydroxytryptamine (5-HT)
and adrenaline show synergism in human platelet
aggregation. This study was conducted to examine
the mechanism(s) of synergistic interaction of 5-HT
and platelet activating factor (PAF) in human plate-
lets. We show that PAF, but not 5-HT, increased
platelet aggregation in a concentration-dependent
manner. However, low concentrations of 5-HT (2 µM)
potentiated platelet aggregation induced by sub-
threshold concentration of PAF (40 nM) indicating a
synergistic interaction between the two agonists
and this synergism was blocked by receptor antag-
onists to either 5-HT or PAF. 5-HT also potentiated
the effect of PAF on thromboxane A2 (TXA2) forma-
tion and phosphorylation of extracellularly regulated
mitogen-activated protein kinases (ERK1/2). The
synergism of 5-HT and PAF in platelet aggregation
was inhibited by calcium (Ca2+) channel blockers,
verapamil and diltiazem, phospholipase C (PLC)
inhibitor, U73122, cyclooxygenase (COX) inhibitor,
indomethacin, and MEK inhibitor, PD98059. These
data suggest that synergistic effect of 5-HT and PAF
on human platelet aggregation involves activation of
PLC/Ca2+, COX and MAP kinase pathways.
Keywords: platelet aggregation, PAF, 5-HT, MAP kinase,
synergism
Introduction
Platelets play an important role in maintaining the vas-
cular integrity and haemostasis. Upon vascular damage,
platelets undergo rapid changes; become more spheri-
cal, extrude pseudopodia and activate their fibrinogen
receptors leading to aggregation. During this process,
platelets release granule contents and substances that
act in autocrine fashion to further enhance aggregation
(Siess, 1989; Brass et al., 1993). We, and others have
shown that various platelet agonists at low concent-
rations elicit synergistic interactions (Ware et al., 1987;
Shah and Saeed, 1995; Saeed et al., 1997; Masini et
al., 1998; Shah et al., 1999; Francesconi et al., 2000).
However, the molecular basis of such an interaction is
not well understood.
Most of the platelet agonists, like thrombin, ADP, PAF,
epinephrine and 5-HT, interact with their transmem-
brane receptors on platelets coupled to GTP binding
proteins (G proteins). The G-proteins mediate a variety
of cellular processes by activating different effector
molecules, including adenylyl cyclase, inositol phospho-
lipid-specific phospholipase C (PLC) or ion channels
(Siess et al., 1989; Exton, 1996). In platelets, stimulation
of receptors coupled to Gq protein (e.g., by 5-HT, PAF or
thrombin) leads to activation of PLC and thus generation
of second messengers, diacylglycerol (DAG) and ino-
sitol-1,4,5-triphosphate (IP3), which results in the acti-
vation of protein kinase C (PKC) and the mobilization of
intracellular Ca2+, respectively (Obberghen-Schilling and
Pouyssegur, 1993). Both Ca2+ and PKC stimulate plate-
let aggregation and also elicit synergism in platelets
(Crabos et al., 1992). Consistent with the potential
involvement of Gq/PLC pathway, the deficiency of Gq
protein in transgenic mice leads to impairment of agonist-
induced platelet aggregation (Offermans et al., 1997).
PAF, a phospholipid mediator, is a very strong platelet
activator and human platelets show high affinity binding
sites for this agonist. It also induces adhesion of
platelets to the endothelium in the presence of activated
leukocytes (Hirafuji and Shinoda, 1991). PAF is also
known to play an important role in various patho-
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physiological conditions that include modulation of blood
pressure, hypotension, cardiac dysfunction in cardiac
anaphylaxis, and hemorrhagic, traumatic, and septic shock
syndromes (Anderson et al., 1991; Montrucchio et al.,
2000). Because of its ability to stimulate endothelial
migration and angiogenesis, a potential role of PAF in
atherosclerosis was suggested (Montrucchio et al., 2000).
PAF is also known as a potent stimulator of throm-
boxane A2 (TXA2) production in human platelets.
Another platelet agonist, 5-hydroxytryptamine (5-HT),
is released by aggregating platelets at the site of vas-
cular damage and this process can be augmented by
PAF (Bailey et al., 2000). 5-HT is widely distributed in
the body and sub-serves many functions. The type 2
receptors for 5-HT (5-HT2) mediate many physiological
functions that include increase in arterial constriction,
modulation of perception, mood, feeding behaviour, and
platelet aggregation (Roth et al., 1998; Robertson, 1991).
Very little 5-HT is free in plasma, most being stored in
dense granules of platelets. However, local platelet acti-
vation and subsequent 5-HT release can present free 5-
HT to peripheral tissues that can contribute to a range
of cardiovascular problems, including portal hyperten-
sion (Robertson, 1991) and vasoconstriction (Roth et
al., 1998). High plasma 5-HT levels are found in primary
pulmonary hypertension (Kereveur et al., 2000) and in
patients with bladder cancer (Pawlak et al., 2000).
Similarly 5-HT2A receptor densities tend to increase in
depression (Mendelson, 2000). Like PAF, 5-HT also
shows mitogenic effects in cardiovascular system (Koba
et al., 2000). It enhances the atherogenic and mitogenic
effects of low-density lipoproteins (LDL) in aortic smooth
muscles (Koba et al., 2000). Combined TXA2 and 5-HT2
receptor blockade is proposed to prevent coronary artery
thrombosis (Willerson et al., 1990).
PAF enhances vasoconstriction of the coronary arteri-
oles (DeFily et al., 1996) and at the inflammatory coro-
nary lesions in vivo by itself as well as in a synergistic
manner with 5-HT (Kozai et al., 1997). Because of the
close interaction between the two agonists (PAF and 5-
HT) and their importance in thrombosis, hypertension
and atherosclerosis, this study was conducted to ex-
amine the mechanism(s) of synergism between 5-HT
and PAF during platelet aggregation. We show that
synergistic interaction of 5-HT and PAF is mediated
through PLC/Ca2+ and cyclooxygenase pathways and is
modulated by nitric oxide.
Materials and Methods
Materials
PAF, 5-HT, cyproheptadine methysergide, indomethacin,
diltiazem, verapamil, chelerythrine and wortmannin were
purchased from the Sigma Chemical Co. (St. Louis,
MO. USA). U73122 and SNAP were from Alexis LC
Labs (UK). All other chemicals were of the highest purity
grade available.
Preparation of human platelets 
Blood was taken by venous-puncture from normal
human volunteers reported to be free of medication for
one week. Blood samples were mixed with 3.8% (w/v)
sodium citrate solution (9:1) and centrifuged at 260 g for
15 min at 20oC to obtain platelet rich plasma (PRP).
Platelet count was determined by phase contrast
microscopy and all aggregation studies were carried out
at 37oC with PRP having platelet counts between 2.5
and 3.0x108/ml of plasma (Saeed et al., 1997).
Measurement of platelet aggregation
Aggregation was monitored using a Dual-channel
Lumi-aggregometer (Model 400 Chronolog Corporation,
Chicago, USA) using 0.45 ml aliquots of PRP. The final
volume was made up to 0.5 ml with the test drug dis-
solved either in normal saline or appropriate vehicle
known to be devoid of any effect on aggregation. Aggre-
gation was induced with PAF and sub-threshold con-
centration determined. To obtain the synergistic effect of
PAF and 5-HT, we added low concentrations of these
agonists. The anti-aggregatory effects of different com-
pounds were studied by pretreatment of PRP with vari-
ous inhibitors for one min followed by addition of the
sub-threshold concentrations of PAF and 5-HT. The
resulting aggregation was recorded for 5 min after chal-
lenge by the change in light transmission as a function
of time. Once the anti-platelet activity of various inhi-
bitors against agonists was established, dose-response
curves were constructed to calculate the IC50 values of
the agonists and inhibitors. 
Thromboxane formation in platelets
Arachidonic acid metabolism and thromboxane A2 (TXA2)
formation were studied as described previously (Saeed
et al., 1997). For these studies, human blood platelets
were routinely obtained in plastic bags containing 30-40
ml of concentrated PRP from The Aga Khan University
Hospital Clinical laboratory, Karachi. 
Immunoblot analysis of ERK1/2 
Platelets were stimulated with PAF at 37oC, lysed with
an equal volume of 2 X Laemmli’s sample buffer con-
taining 5% β-mercaptoethanol. The samples were heat-
ed at 95oC for 5 minutes, electrophoresed on SDS-
PAGE (10%) gels and transferred to PDVF nylon
membranes. Membranes were incubated overnight with
phospho-MAP kinase (p42/44) primary antibody (New
England Biolabs) diluted in TBST. Primary antibody was
removed and blots washed three times with TBST
before adding the horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature. After
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washing six times with TBST, blots were exposed to
enhanced chemiluminescence reagent (Amersham
Pharmacia) and films developed.
Results 
Treatment of PRP with PAF showed concentration-
dependent aggregatory effects on human platelets
(Figure 1A). In contrast, 5-HT had no effect on platelet
aggregation up to 200 µM (data not shown). But very
low concentrations of 5-HT (2 µM) caused marked
potentiation of aggregation response mediated by sub-
threshold concentration of PAF (40 nM) suggesting a
synergism between the two agonists (Figure 1B). To
examine the molecular basis of this synergism, we used
the selective inhibitors of various signalling pathways.
Pretreatment of PRP with 5-HT receptor antagonist,
Figure 1. (A) Concentration-dependent effects of PAF on human platelet aggregation. PRP was treated with the agonist and platelet aggregation recorded for
5 min. (B) Tracings from representative experiments showing synergism of 5-HT (2 µ M) and PAF (40 nM). (C) The synergistic effect of 5-HT and PAF on platelet
aggregation is blocked by 5-HT receptor antagonist, cyproheptadine (D) phospholipase C inhibitor, U73122 (E) and PAF antagonist WEB2086. Inhibitors were
added one min before the agonists. Control means platelet aggregation induced by 5-HT (2 µM) plus PAF (40 nM) (n=5).
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cyproheptadine (IC50=4nM) was effective in blocking
synergism of 5-HT and PAF (Figure 1C). Consistent with
the notion that both PAF and 5-HT activate Gq/PLC,
pretreatment of PRP with PLC inhibitor, U73122, com-
pletely inhibited the synergistic effect of PAF and 5-HT
with an IC50 of 10 ± 3 µM (Figure 1D).
Like cyproheptadine, PAF receptor antagonist WEB
2086 (IC50=0.5 µM) also showed marked inhibition indi-
cating that the synergistic effect of 5-HT and PAF was
dependent on functional receptors for both agonists
(Figure 1E). Since activation of PLC leads to an
increase in cytosolic Ca2+ due to its release from internal
stores by inositol triphosphate (IP3) or through store-
depleted Ca+2-influx (Heemskerk and Sage, 1994), we
examined the effect of Ca2+ channel blockers (verapamil
and diltiazem) on platelet aggregation. The synergistic
effect of low concentrations of PAF (40 nM) and 5-HT (2
µM) was markedly inhibited by low concentrations of
verapamil and diltiazem with IC50 of 5 and 8 µM, respec-
tively (Table 1). In contrast, PKC inhibitor, chelerythrine,
had no inhibitory effect, excluding any role of PKC in this
cascade (data not shown). These data suggest that
platelet aggregation mediated by co-addition of sub-
threshold concentrations of these agonists predomin-
antly is Ca2+-dependent and also occurs through influx
of calcium through receptor-operated calcium channels.
PAF is considered to be a potent activator of TXA2
formation through activation of cyclooxygenase-1 (COX-
1). To examine if these two agonists show synergism on
COX-1 activity, we measured TXA2 formation in agonist-
treated platelets. Similar to its effect on platelet aggre-
gation, 5-HT markedly potentiated the TXA2 formation
Table 1. Effects of various inhibitors on platelet aggregation mediated by
synergistic interaction of sub-threshold concentrations of PAF (40 nM) plus
5-HT (2 µM) and PAF alone (800 nM)




Cyproheptadine *4.00 ± 0.020 *40 ± 4.50
Methysergide *55.00 ± 2.200 52 ± 3.40
WEB 2086 0.50 ± 0.080 48 ± 5.50
Verapamil 8.00 ± 0.100 20 ± 3.40
Diltiazem 5.20 ± 0.400 15 ± 2.00
PD98059 3.00 ± 0.300 4.0 ± 0.01
Indomethacin 0.25 ± 0.001 9 ± 1.20
U73122 10.00 ± 2.800 NE 
SNAP 0.28 ± 0.040 ND
Wortmannin 0.62 ± 0.100 ND
Data is mean ± SEM (n = 5-7) and is indicated as half-maximal effect (IC50)
of the inhibitors. (*) Means concentrations in nM. (NE = no effect and
ND = not done) Figure 2. Effects of 5-HT and PAF on thromboxane A2 (TXA2) formation in
human platelets. Low concentrations of 5-HT (2 µM) potentiate the effect of
PAF (40 nM) on TXA2 formation in human platelets (n=7).
Figure 3. (A) Cyclooxygenase (COX) inhibitor, indomethacin, (B) Nitric oxide donor, SNAP, inhibits platelet aggregation induced by co-addition of sub-threshold
concentrations of 5-HT and PAF. Inhibitors were added one min before the addition of agonists. Control means platelet aggregation induced by 5-HT (2 µM)
plus PAF (40 nM) (n=7).
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by low concentrations of PAF (40 nM) as shown in
Figure 2. Moreover, the selective COX-1 inhibitor, indo-
methacin, completely blocked platelet aggregation at
very low concentrations (IC50=0.25 µM) suggesting the
potential involvement of COX-1 in this synergism (Figure
3A). Recent studies indicate an important role of nitric
oxide (NO) in modulating platelet aggregation (Shah et
al., 1999). An analysis of results show that NO donor,
SNAP, completely blocked platelet aggregation mediat-
ed by synergistic interaction of PAF and 5-HT (Figure
3B). These data provide evidence in support of an
important role for NO in negatively modulating the
human platelet aggregation.
Agonist-stimulation of Gq/PLC/Ca+2 cascade leads to
activation of mitogen-activated protein (MAP) kinases
(Della Roca et al., 1999; Heemskerk and Sage, 1994).
We have recently shown that synergism of adrenaline
and histamine involves phosphorylation of extracellularly
regulated MAP kinases (Shah et al., 2000). Results in
Figure 4A show that PAF stimulated the phosphorylation
of ERK1/2 and 5-HT increased this effect. Pretreatment
of PRP with MEK inhibitor, PD98059, inhibited ERK1/2
activation induced by co-addition of sub-threshold con-
centrations of PAF and 5-HT. Similarly, PD98059 also
inhibited platelet aggregation in response to agonist
synergism (Figure 4B). Since MEK inhibitor, PD98059,
is reported to directly inhibit purified COX-1 and -2
(Borsch-Haubold et al., 1998), we examined the effect
of PD98059 on arachidonic acid metabolism and TXA2
formation. An analysis of results show that PD98059
also inhibits agonist-induced TXA2 production with an
IC50 of 5 ± 0.3 µM. Thus, it is possible that the inhibitory
effect of PD98059 on platelet aggregation is mediated
through inhibition of COX activity. We also examined the
effect of inhibitors against PAF alone and the data is
given in Table 1. Our results show that inhibitors of
various signalling pathways inhibited PAF plus 5-HT
induced aggregation at lower IC50 values as compared
to the IC50 values obtained against PAF alone (Table 1).
Phosphatidylinositol 3-kinase (PI 3-kinase), is activated
by GPCRs and growth factors, and plays an important
role in platelet aggregation. The selective inhibitor of PI
3-kinase, wortmannin, is reported to block the aggre-
gation response induced by synergism of 5-HT and
adrenaline (Shah and Saeed, 1995). Our results show
that wortmannin inhibited platelet aggregation (IC50=620
nM) induced by the synergism of PAF and 5-HT (Table
1). 
Discussion
Most of the platelet agonists, which interact with G-
protein coupled receptors, exert their effects through
activation of either Gq/PLC (e.g. PAF, thrombin) or Gi/
adenylyl cyclase (e.g., adrenaline) in platelets (Siess et
al., 1989; Brass et al., 1993). The second messengers,
Ca2+ and PKC generated in response to Gq/PLC
activation bring about coordinated changes leading
towards platelet aggregation (Crabos et al., 1992;
Heemskerk and Sage, 1994). The platelet aggregation
by sub-threshold concentrations of PAF and 5-HT were
inhibited by receptor antagonists, and inhibitors of PLC
and MAP kinase and Cox. We (Shah et al., 1999; 2000),
and others have recently shown that concomitant
activation of Gi and Gq protein-linked signalling path-
ways results in aggregation of human platelets. How-
ever, the present data demonstrate that activation of Gq
protein by two different agonists at sub-threshold
concentrations is equally potent in eliciting the aggre-
gation response by platelets. 
In platelets, PAF and 5-HT cause stimulation of Gq
protein followed by activation of PLC. This explains why
U73122, a selective inhibitor of PLC, shows strong inhi-
bitory effects on platelet aggregation induced by co-
activation by these agonists. Further, PLC activation
leads to generation of IP3, release of Ca2+ from internal
Figure 4. (A) Effects of 5-HT and PAF on the phosphorylation of extra-
cellularly regulated MAP kinases (ERK1/2) in human platelets. PD98059
blocks the ERK1/2 activation. (B) Concentration-dependent effects of MEK
inhibitor, PD98059, on platelet aggregation induced by co-addition of 5-HT
and PAF. Control means platelet aggregation induced by 5-HT (2 µM) plus
PAF (40 nM) (n=6).
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stores and eventually store-depleted Ca2+ influx (Hee-
mskerk and Sage, 1994) that was inhibited by Ca2+-
channel blockers (verapamil and diltiazem). Moreover,
the increase in cytosolic Ca2+ causes activation of PLA2
and COX-1 activity, thus stimulating TXA2 formation
(Heemskerk and Sage, 1994). Since the synergism of
these agonists was inhibited by indomethacin, a COX-1
inhibitor, it seems that the agonist-mediated synergism
follows activation of COX-1 distal to PLC/Ca2+ activa-
tion. We tested if increasing the intracellular nitric oxide
(NO) levels by NO donor and thus activating cGMP
kinase has any inhibitory effect on platelet aggregation.
Our results show that NO donor, SNAP, inhibited platelet
aggregation at very low concentrations (IC50=0.3 µM)
suggesting that PAF and 5-HT synergism is highly
sensitive to NO generation in human platelets (Figure
3B). However, the role of PKC in the present study was
excluded as PKC inhibition had no effect on the syn-
ergism of PAF and 5-HT in platelets.
The cyclic nucleotides, cAMP and cGMP, through acti-
vation of cAMP- and cGMP-dependent protein kinases,
down-regulate the Ca2+ responses and thus inhibit
platelet aggregation (Heemskerk and Sage, 1994). In
fact platelets are abundant in cAMP and cGMP-depen-
dent protein kinases and these kinases can inhibit PLC-
induced IP3 production through inactivation of IP3 and
TXA2 receptors (Heemskerk and Sage, 1994; Wang et
al., 1998). 
The inhibition of PAF/5-HT synergism by MEK inhibi-
tor, PD98059, suggests the involvement of MAP kinase
that is known to be distal to Gq/PLC (Della Roca et al.,
1997; 1999). PAF through activation of Gq/PLC is report-
ed to activate ERK1/2 MAP kinases through different
signalling pathways that include PI 3-kinase, tyrosine
kinases such as proline-rich tyrosine kinase (Pyk2),
Ras/Raf and MEK1/2 (Ishii and Shimizu, 2000; Miike et
al., 2000). ERK1/2 phosphorylation can activate cPLA2
leading to production of prostaglandins and TXA2
through activation of COX (Ishii and Shimizu, 2000). In
fact, cPLA2 is also a potential target of activation by
increase in cytosolic Ca2+. Taken together, it appears as
both Ca2+ and MAP kinases play an important role
during synergistic interaction of 5-HT and PAF in human
platelets.
The selective MEK inhibitor, PD98059, is also known
to inhibit the COX-1 and -2 activities (Borsch-Haubold et
al., 1998; McNicole et al., 1998). Using purified COX-1
and -2, Borsch-Haubold et al., (1998) showed that
PD98059 inhibited arachidonic acid metabolism and
TXA2 formation at quite low concentrations (IC50=0.8
µM). These authors reported that higher concentrations
of PD98059 were required to inhibit platelet aggregation
induced by arachidonic acid, thrombin and collagen.
Under our experimental conditions, PD98059 inhibited
both TXA2 production and platelet aggregation with IC50
of 5 and 3 µM, respectively (Figures 4A & B). There-
fore, the possibility that inhibition of agonist-induced
platelet aggregation by PD98059 is due to blockade of
COX activity cannot be ignored.
Our previous studies have shown an important role of
PI 3-kinase in 5-HT mediated potentiation of platelet
aggregation by adrenaline (Shah and Saeed, 1995). In
addition, the inhibitors of PI 3-kinase block platelet
aggregation induced by low, but not high, concentrations
of PAF (Lauener et al., 1999). More recently, PI 3-kinase
was shown to be involved in the thrombopoietin (TPO)
mediated potentiation of platelet function. TPO stimulat-
ed ERK1/2 MAP kinase activation by increasing the
association of tyrosine phosphorylated Gab1 with p85
subunit of PI 3-kinase. Our data show that PI 3-kinase
inhibitor, wortmannin, abolished platelet aggregation only at
higher concentrations (1 µM). Since higher concentrations
of wortmannin (>100 nM) are known to inhibit other
signaling proteins such as myosin light chain kinase, in
platelets, the involvement of PI 3-kinase in this cascade
cannot be over-emphasized.
The mechanism of synergism among various platelet
agonists is reported to occur due to activation of Ca2+
signalling cascade. A rise in Ca2+ induced by first agonist
primes platelets for an enhanced functional response to
the second agonist (Ware et al., 1987; Shah et al.,
1999). Ca2+ plays pivotal role in platelet aggregation
(Heemskerk and Sage, 1994; Shah et al., 1998). Inter-
ruption in the process of Ca2+ activation either through
Ca2+ channels (Shah et al., 1998) or Gq proteins can
Figure 5. Signalling pathways involved in the synergistic interaction of
GPCR agonists, 5-HT and PAF. Both agonists activate phosphoinositide-
linked G protein (Gq) and phospholipase C (PLC), which leads to generation
of inositol triphosphate (IP3) and diacylglycerol (DAG), and thus release of
Ca2+ from internal stores and activation of protein kinase C (PKC). The
agonist-induced store-depletion of Ca2+ also increases Ca2+ influx through
membranes. Both Ca2+ and PKC are involved in the release of granule
contents and activation of phospholipase A2 (PLA2), thus generation of
potent agonist, thromboxane A2 (TXA2), which in an autocrine fashion acts
on platelets through Gq protein. Nitric oxide (NO) inhibits platelet aggre-
gation through production of cyclic GMP (cGMP) from guanylate cyclase.
The cGMP activates protein kinase G (PKG) that exerts inhibitory effect on
platelet aggregation through phosphorylation of PLC, Ca2+-channels or IP3-
receptor.
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interfere with the activation of platelets. Offermanns et
al. (1999) showed that Gq protein-deficient mice lack the
ability of platelet aggregation. Co-activation of PAF and
5-HT receptors on platelets seems to follow the Gq/PLC/
Ca2+, and inhibitors of PLC, MAP Kinase and COX,
(Figure 5). The synergism among various platelet agonists
in the body is of great clinical significance as it can lead
to marked potentiation of the platelet activation and thus
alter the cardiovascular physiology. In conclusion, our
studies show that sub-threshold concentrations of 5-HT
potentiate the platelet aggregation mediated by PAF in
vitro, and this synergism is negatively modulated by
nitric oxide donor, SNAP, suggesting a potential regulatory
role of nitric oxide in platelet function. 
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